David R Rubinow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7571235/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reduction in Left Frontal Alpha Oscillations by Transcranial Alternating Current Stimulation in Major Depressive Disorder Is Context Dependent in a Randomized Clinical Trial. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 302-311.	1.5	15
2	Autonomic and Depression Symptoms in Parkinson's Disease: Clinical Evidence for Overlapping Physiology. Journal of Parkinson's Disease, 2022, 12, 1059-1067.	2.8	8
3	Transcriptome-wide association study for postpartum depression implicates altered B-cell activation and insulin resistance. Molecular Psychiatry, 2022, 27, 2858-2867.	7.9	9
4	Methods for characterizing ovarian and adrenal hormone variability and mood relationships in peripubertal females. Psychoneuroendocrinology, 2022, 141, 105747.	2.7	8
5	Baseline anxiety-sensitivity to estradiol fluctuations predicts anxiety symptom response to transdermal estradiol treatment in perimenopausal women – A randomized clinical trial. Psychoneuroendocrinology, 2022, 143, 105851.	2.7	9
6	HPA axis regulation and epigenetic programming of immune-related genes in chronically stressed and non-stressed mid-life women. Brain, Behavior, and Immunity, 2021, 92, 49-56.	4.1	16
7	Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors. Journal of Clinical Lipidology, 2021, 15, 151-161.e0.	1.5	4
8	OUP accepted manuscript. Cerebral Cortex, 2021, , .	2.9	7
9	One Small Step for PMDD, One Large Step for Affective Disorders. American Journal of Psychiatry, 2021, 178, 215-217.	7.2	3
10	Disinhibition of right inferior frontal gyrus underlies alpha asymmetry in women with low testosterone. Biological Psychology, 2021, 161, 108061.	2.2	4
11	Subgenual cingulate resting regional cerebral blood flow in premenstrual dysphoric disorder: differential regulation by ovarian steroids and preliminary evidence for an association with expression of ESC/E(Z) complex genes. Translational Psychiatry, 2021, 11, 206.	4.8	4
12	Altered estradiol-dependent cellular Ca2+ homeostasis and endoplasmic reticulum stress response in Premenstrual Dysphoric Disorder. Molecular Psychiatry, 2021, 26, 6963-6974.	7.9	11
13	Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids― American Journal of Psychiatry, 2021, 178, 572-573.	7.2	0
14	The Cortisol and ACTH Response to Dex/CRH Testing in Women With and Without Perimenopausal Depression. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3007-3018.	3.6	5
15	The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression. Menopause, 2021, 28, 369-383.	2.0	12
16	In search of sex-related mediators of affective illness. Biology of Sex Differences, 2021, 12, 55.	4.1	8
17	Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study. Archives of Women's Mental Health, 2020, 23, 401-412.	2.6	12
18	A case study of weekly tACS for the treatment of major depressive disorder. Brain Stimulation, 2020, 13, 576-577.	1.6	25

#	Article	IF	CITATIONS
19	The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2050-e2060.	3.6	10
20	IL-6 Response to Psychosocial Stress Predicts 12-month Changes in Cardiometabolic Biomarkers in Perimenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3757-e3765.	3.6	5
21	In vitro model of perimenopausal depression implicates steroid metabolic and proinflammatory genes. Molecular Psychiatry, 2020, 26, 3266-3276.	7.9	7
22	Test-statistic inflation in methylome-wide association studies. Epigenetics, 2020, 15, 1163-1166.	2.7	20
23	Sex differences and the neurobiology of affective disorders. Neuropsychopharmacology, 2019, 44, 111-128.	5.4	174
24	Brexanolone injection for post-partum depression treatment – Authors' reply. Lancet, The, 2019, 394, 380.	13.7	2
25	Trial of SAGE-217 in Patients with Major Depressive Disorder. New England Journal of Medicine, 2019, 381, 903-911.	27.0	156
26	Double-blind, randomized pilot clinical trial targeting alpha oscillations with transcranial alternating current stimulation (tACS) for the treatment of major depressive disorder (MDD). Translational Psychiatry, 2019, 9, 106.	4.8	116
27	Safety of Estradiol Treatment in Perimenopausal Asymptomatic Women—Reply. JAMA Psychiatry, 2018, 75, 529.	11.0	0
28	Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition. JAMA Psychiatry, 2018, 75, 149.	11.0	140
29	Emotionâ€related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder. Journal of Clinical Psychology, 2018, 74, 579-593.	1.9	18
30	Early Life Abuse Moderates the Effects of Intranasal Oxytocin on Symptoms of Premenstrual Dysphoric Disorder: Preliminary Evidence From a Placebo-Controlled Trial. Frontiers in Psychiatry, 2018, 9, 547.	2.6	10
31	Progesterone and plasma metabolites in women with and in those without premenstrual dysphoric disorder. Depression and Anxiety, 2018, 35, 1168-1177.	4.1	5
32	Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet, The, 2018, 392, 1058-1070.	13.7	547
33	The role of ovarian steroids in affective disorders. Current Opinion in Behavioral Sciences, 2018, 23, 103-112.	3.9	14
34	Is there a role for reproductive steroids in the etiology and treatment of affective disorders?. Dialogues in Clinical Neuroscience, 2018, 20, 187-196.	3.7	25
35	Hormonal gain control of a medial preoptic area social reward circuit. Nature Neuroscience, 2017, 20, 449-458.	14.8	207
36	Depression during the menopause transition: impact on quality of life, social adjustment, and disability. Archives of Women's Mental Health, 2017, 20, 273-282.	2.6	38

#	Article	IF	CITATIONS
37	Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Human Psychopharmacology, 2017, 32, e2576.	1.5	104
38	Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. American Journal of Psychiatry, 2017, 174, 980-989.	7.2	123
39	Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Lancet Psychiatry,the, 2017, 4, 477-485.	7.4	199
40	Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet, The, 2017, 390, 480-489.	13.7	311
41	HPA axis reactivity to pharmacologic and psychological stressors in euthymic women with histories of postpartum versus major depression. Archives of Women's Mental Health, 2017, 20, 411-420.	2.6	12
42	Perimenopausal depression and early menopause: cause or consequence?. Menopause, 2017, 24, 1333-1335.	2.0	5
43	Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial. Depression and Anxiety, 2017, 34, 908-917.	4.1	20
44	Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS). American Journal of Psychiatry, 2017, 174, 51-59.	7.2	67
45	In immune defense: redefining the role of the immune system in chronic disease. Dialogues in Clinical Neuroscience, 2017, 19, 19-26.	3.7	15
46	The Effects of Trauma History and Prenatal Affective Symptoms on Obstetric Outcomes. Journal of Traumatic Stress, 2016, 29, 245-252.	1.8	34
47	Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause, 2016, 23, 257-266.	2.0	99
48	Reproductive Steroid Regulation of Mood and Behavior. , 2016, 6, 1135-1160.		129
49	Sex, Drugs, and the Neurobiology of the Placebo Effect. Biological Psychiatry, 2016, 79, 788-789.	1.3	1
50	Naturally Occurring Changes in Estradiol Concentrations in the Menopause Transition Predict Morning Cortisol and Negative Mood in Perimenopausal Depression. Clinical Psychological Science, 2016, 4, 919-935.	4.0	48
51	Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder. Psychoneuroendocrinology, 2016, 67, 142-152.	2.7	46
52	Sex differences in visuospatial abilities persist during induced hypogonadism. Neuropsychologia, 2016, 81, 219-229.	1.6	14
53	5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. Neuropsychopharmacology, 2016, 41, 1093-1102.	5.4	107
54	EFFICACY OF ESTRADIOL IN PERIMENOPAUSAL DEPRESSION: SO MUCH PROMISE AND SO FEW ANSWERS. Depression and Anxiety, 2015, 32, 539-549.	4.1	64

#	Article	IF	CITATIONS
55	Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression. JAMA Psychiatry, 2015, 72, 714.	11.0	155
56	Maternally responsive neurons in the bed nucleus of the stria terminalis and medial preoptic area: Putative circuits for regulating anxiety and reward. Frontiers in Neuroendocrinology, 2015, 38, 65-72.	5.2	31
57	The role of reproductive hormones in postpartum depression. CNS Spectrums, 2015, 20, 48-59.	1.2	256
58	Response to Pinta. American Journal of Psychiatry, 2015, 172, 202-202.	7.2	0
59	Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology, 2014, 231, 3557-3567.	3.1	81
60	Estradiol modulates anhedonia and behavioral despair in rats and negative affect in a subgroup of women at high risk for postpartum depression. Physiology and Behavior, 2013, 119, 137-144.	2.1	58
61	Abnormalities of Dorsolateral Prefrontal Function in Women With Premenstrual Dysphoric Disorder: A Multimodal Neuroimaging Study. American Journal of Psychiatry, 2013, 170, 305-314.	7.2	84
62	Estrogen effects on the forced swim test differ in two outbred rat strains. Physiology and Behavior, 2012, 106, 81-86.	2.1	22
63	Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater. Depression and Anxiety, 2011, 28, 282-296.	4.1	8
64	Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater. Depression and Anxiety, 2011, 28, E1-E15.	4.1	20
65	DSM-V: an opportunity to embrace the future of psychiatric diagnosis. Archives of Women's Mental Health, 2010, 13, 3-4.	2.6	0
66	Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. Journal of Clinical Endocrinology and Metabolism, 2010, 95, s1-s66.	3.6	512
67	A Cross-Sectional Evaluation of Perimenopausal Depression. Journal of Clinical Psychiatry, 2008, 69, 973-980.	2.2	57
68	Menstrual cycle phase modulates reward-related neural function in women. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2465-2470.	7.1	474
69	Facial emotion discrimination across the menstrual cycle in women with Premenstrual Dysphoric Disorder (PMDD) and controls. Journal of Affective Disorders, 2007, 104, 37-44.	4.1	44
70	Gonadal steroid regulation of mood: The lessons of premenstrual syndromeâ~†. Frontiers in Neuroendocrinology, 2006, 27, 210-216.	5.2	107
71	Testosterone Suppression of CRH-Stimulated Cortisol in Men. Neuropsychopharmacology, 2005, 30, 1906-1912.	5.4	126
72	Sex-Related Differences in Stimulated Hypothalamic-Pituitary-Adrenal Axis during Induced Gonadal Suppression. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4224-4231.	3.6	79

#	Article	IF	CITATIONS
73	Dehydroepiandrosterone Monotherapy in Midlife-Onset Major and Minor Depression. Archives of General Psychiatry, 2005, 62, 154.	12.3	221
74	A Longitudinal Evaluation of the Relationship Between Reproductive Status and Mood in Perimenopausal Women. American Journal of Psychiatry, 2004, 161, 2238-2244.	7.2	211
75	Current and lifetime psychiatric illness in women with Turner syndrome. Gynecological Endocrinology, 2004, 19, 313-319.	1.7	68
76	Sex-dependent modulation of treatment response. Dialogues in Clinical Neuroscience, 2004, 6, 39-51.	3.7	19
77	Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for research. Journal of Psychiatric Research, 2003, 37, 75-83.	3.1	54
78	Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biological Psychiatry, 2003, 54, 757-762.	1.3	77
79	Differential Menstrual Cycle Regulation of Hypothalamic-Pituitary-Adrenal Axis in Women with Premenstrual Syndrome and Controls. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3057-3063.	3.6	149
80	Sex-related differences in MAPKs activation in rat astrocytes: effects of estrogen on cell death. Molecular Brain Research, 2002, 103, 1-11.	2.3	59
81	Effects of ovarian hormones on human cortical excitability. Annals of Neurology, 2002, 51, 599-603.	5.3	273
82	Gonadal steroids, brain, and behavior: role of context. Dialogues in Clinical Neuroscience, 2002, 4, 123-137.	3.7	27
83	Sex-related differences in MAPKs activation in rat astrocytes: effects of estrogen on cell death. Molecular Brain Research, 2002, 103, 1-11.	2.3	23
84	Estrogen protects against ??-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. NeuroReport, 2001, 12, 1919-1923.	1.2	116
85	Effects of the Menstrual Cycle on Measures of Personality in Women With Premenstrual Syndrome. Journal of Clinical Psychiatry, 2001, 62, 337-342.	2.2	29
86	Estrogen replacement in perimenopause-related depression: A preliminary report. American Journal of Obstetrics and Gynecology, 2000, 183, 414-420.	1.3	539
87	Estrogen–serotonin interactions: implications for affective regulation. Biological Psychiatry, 1998, 44, 839-850.	1.3	444
88	Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome. New England Journal of Medicine, 1998, 338, 209-216.	27.0	618
89	Abnormal Facial Emotion Recognition in Depression:. Behavior Modification, 1998, 22, 192-204.	1.6	80
90	Effects of Leuprolide-Induced Hypogonadism and Testosterone Replacement on Sleep, Melatonin, and Prolactin Secretion in Men. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3203-3207.	3.6	39

#	Article	IF	CITATIONS
91	Effect of Menstrual Cycle Phase on Neuroendocrine and Behavioral Responses to the Serotonin Agonistm-Chlorophenylpiperazine in Women with Premenstrual Syndrome and Controls1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1220-1228.	3.6	74
92	Nimodipine Increases CSF Somatostatin in Affectively Ill Patients. Neuropsychopharmacology, 1995, 13, 75-83.	5.4	16
93	Nimodipine Increases CSF Somatostatin in Affectively Ill Patients. Neuropsychopharmacology, 1995, 13, 75-83.	5.4	1
94	Impaired recognition of affect in facial expression in depressed patients. Biological Psychiatry, 1992, 31, 947-953.	1.3	220
95	Cerebrospinal Fluid Immunoreactive Cortieotropin-Releasing Hormone and Adrenocorticotropin Secretion in Cushing's Disease and Major Depression: Potential Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 260-271.	3.6	154
96	Hypothalamic-Pituitary-Adrenal Function in Patients with the Premenstrual Syndrome. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1158-1162.	3.6	85
97	Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. American Journal of Obstetrics and Gynecology, 1988, 158, 5-11.	1.3	225
98	Conditioning and Sensitisation in the Longitudinal Course of Affective Illness. British Journal of Psychiatry, 1986, 149, 191-201.	2.8	346